Sarfaraz K. Niazi, PhD, outlines how President Joe Biden's new budget for 2025 could impact biosimilars, including provisions to clear up confusion surrounding interchangeable products.
The FY 2025 US budget announced on March 11 is one of the rare admissions of why the cost of pharmaceuticals per capita is the highest globally. The FY 2025 budget includes several legislative proposals supporting the FDA's efforts to protect American consumers and patients. Of the dozens of proposals, the significant ones for the generic industry are:
The extension of the ingredient listing requirement of parenteral products to chemical drugs.
Amending certain exclusivity provisions for drugs to encourage meaningful innovation and timely competition. FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is seeking such exclusivity and where the data supporting the exclusivity demonstrates the hypothesized effect of the drug and to prevent information on new safety risks from blocking competition. This approach would continue to reward innovation while allowing earlier access to generic drugs in certain situations.
However, the most relevant suggestion is to eliminate the statutory distinction between the approval standard for biosimilar and interchangeable biosimilar products and deem approved biosimilars interchangeable. The statutory distinction between biosimilars and interchangeable biosimilars has led to confusion and misunderstanding among patients and health care providers about the safety and effectiveness of biosimilars and whether interchangeable biosimilars are safer or more effective than other biosimilars. This proposal would make the US biosimilar program more consistent with current scientific understanding and the approach adopted by other major regulatory jurisdictions, such as the European Union, where biosimilars are interchangeable with their respective reference products upon approval. Further, this proposal is expected to increase the uptake of biosimilars, with potential downstream effects of increasing competition, access, and affordability.
However, the FDA is taking a different approach when FDA Commissioner Robert Califf, MD, said approval from Congress is still the best pathway to making the change than just declaring biosimilars interchangeable; the FDA is seeking to amend section 351 of the Public Health Service Act to no longer include a separate statutory standard for a determination of interchangeability and to deem all approved biosimilars to be interchangeable with their respective reference products. This is a wrong decision by the FDA, since such legislative changes are difficult to achieve, and often get tossed out due to many conflicts of interest. Notably, the US Senate has a bill pending to do just that, and I have provided support through my publications and meetings with senators, but it is going nowhere. Before the release of the FY 2025 budget, I was consulted by the White House, and I was able to present a solid scientific argument, avoiding cost savings as the primary reason. I am glad to see this provision in the budget, but I am not sure if the FDA fully supports it and instead waits for the amendment to 351(k), and indeed, the big pharma has already launched a campaign to prevent this from happening.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.